AIR001 (sodium nitrite inhalation solution) ( DrugBank: Nitrite )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	2

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01725256 (ClinicalTrials.gov)	November 2012	8/11/2012	A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)	A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)	Pulmonary Arterial Hypertension	Drug: AIR001 (sodium nitrite inhalation solution)	Aires Pharmaceuticals, Inc.	NULL	Terminated	18 Years	75 Years	Both	29	Phase 2	United States;Australia;Hungary
2	NCT01409122 (ClinicalTrials.gov)	July 2011	1/8/2011	Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	A Phase 1, Placebo Controlled, Blinded, Multiple Dose Escalation Study of AIR001 (Sodium Nitrite Inhalation Solution) in Healthy Subjects, an Assessment of the Tolerability in Combination With Oral Sildenafil, and an Open-Label Study of Multiple Dose AIR001 in Patients With Pulmonary Arterial Hypertension	Pulmonary Hypertension;Pulmonary Arterial Hypertension	Drug: 15 mg sodium nitrite inhalation solution;Drug: 90 mg sodium nitrite inhalation solution;Drug: 45 mg sodium nitrite inhalation solution;Drug: 120 mg sodium nitrite inhalation solution;Drug: 25% MTD sodium nitrite inhalation solution	Aires Pharmaceuticals, Inc.	NULL	Completed	18 Years	56 Years	Both	42	Phase 1	United States